On July 15, BeOne Medicines rose 3.23% in regular trading, trading at HK$190.9/share, with turnover of HK$246 million. The gain came amid a broad biotech sector rally driven by continued positive sentiment following the release of the National Essential Drug List (2026 Edition).

The updated list, published on July 9 and effective September 1, marks the first revision in eight years and for the first time systematically incorporates innovative drugs into the selection framework. Analysts note that all newly added drugs are already covered by medical insurance, and the deep coordination between the essential drug system and national healthcare reimbursement is expected to significantly accelerate innovative drug penetration into primary healthcare institutions. Brokerages view the policy shift from a price-oriented to a clinical-value-oriented selection logic as a landmark change, directly unlocking grassroots market volume for qualifying innovative drug companies.

Within the Biotechnology sector, the overall sector rose strongly. Among individual stocks, SKB BIO up 10.2%, AKESO up 9.02%, INNOVENT BIO up 7.88%, 3SBIO up 7.13%, REMEGEN up 5.88%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)